Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Novartis discloses EZH2 and EED inhibitors

March 7, 2022

Medshine Discovery identifies new BRD4 inhibitors

March 7, 2022

Shenzhen Chipscreen Biosciences discloses new PTPN11 inhibitors

March 7, 2022

Engineered retinal cells stare daggers at peritoneal tumors

March 4, 2022

Phenanthroline derivative with antitumor activity in liver cancer models

March 4, 2022

Cornell University patents PROTACs targeting BET domain proteins

March 4, 2022

New prodrugs of PIN1 inhibitors discovered at the University of California

March 4, 2022

Abm Therapeutics identifies new AXL/PAK1/c-KIT/RET/MAP4K1 inhibitors

March 4, 2022

Clarity Pharmaceuticals describes new radiopharmaceuticals

March 4, 2022

RedCloud cleared to enter clinic with next-generation EGFR inhibitor H-002 for NSCLC

March 3, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...